Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Congestive heart failure-cell therapy - Angiogene

Drug Profile

Congestive heart failure-cell therapy - Angiogene

Alternative Names: AngioCell™; EPAS1-modified myoblast cell therapy

Latest Information Update: 10 Nov 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Angiogene Inc
  • Class
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 10 Nov 2006 No development reported - Preclinical for Congestive heart failure in Canada (unspecified route)
  • 18 Jun 2003 EPAS1 gene/cell therapy is available for licensing (www.angiogene.com)
  • 17 Jun 2003 Preclinical trials in Congestive heart failure in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top